Michael Tillinger, MD

Title: VP of Clinical Development Wave Life Sciences

Bio: Michael N. Tillinger, MD, is currently VP of clinical development at Wave Life Sciences Ltd. and oversees Wave’s portfolio of therapeutic research and development programs with a focus on genetically defined neurodegenerative diseases. Dr. Tillinger is a board certified anesthesiologist with over 20 years of biopharmaceutical industry experience developing therapies across several therapeutic areas including for neurological disorders. Prior to joining Wave in 2022, he served as the VP of clinical development at X4 Pharmaceuticals and was responsible for development strategy and oversight for compounds within rare diseases areas. Dr. Tillinger received his undergraduate degree and medical degree from Sackler School of Medicine at the Tel Aviv University in Israel.

2023 FUTURES: RNA targeted Therapeutics Sessions Part 2

Continued updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

Jane Larkindale, DPhil

VP of Clinical Science PepGen

Dania Porco, MS, MBA, CGC

Director in Clinical Science BioMarin Pharmaceutical Inc.

Michael Tillinger, MD

VP of Clinical Development Wave Life Sciences